<DOC>
	<DOCNO>NCT00369681</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving rituximab together combination chemotherapy may kill cancer cell . PURPOSE : This phase II trial study well give rituximab together combination chemotherapy work treat patient newly diagnose stage II , stage III , stage IV Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Rituximab Combination Chemotherapy Treating Patients With Newly Diagnosed Stage II , Stage III , Stage IV Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Investigate plasma DNA biomarkers , include plasma clonal immunoglobulin DNA , tumor suppressor gene methylation , Epstein-Barr virus DNA , patient receive rituximab doxorubicin hydrochloride , bleomycin , vinblastine , dacarbazine ( ABVD ) newly diagnose stage II-IV classical Hodgkin 's lymphoma . - Characterize impact rituximab marker . - Characterize relationship marker detection clinical outcome . Secondary - Estimate event-free survival patient newly diagnose Hodgkin 's lymphoma treat rituximab ABVD . - Assess presence Hodgkin 's lymphoma stem cell peripheral blood mononuclear cell baseline , treatment rituximab , treatment ABVD . - Assess whether plasma DNA biomarkers add information fludeoxyglucose F 18 positron emission tomography ( FDG-PET ) assess tumor response . OUTLINE : Patients receive doxorubicin hydrochloride IV , vinblastine IV , bleomycin IV , dacarbazine IV ( ABVD ) day 1 15 course . Patients also receive rituximab IV day -6 , 1 , 8 , 15 , 22 ABVD course 1 day 1 ABVD course 2 , 4 , 6 . Treatment repeat every 28 day 6-8 course absence disease progression unacceptable toxicity . Patients bulky disease may undergo radiotherapy . Plasma sample obtain treatment investigation tumor marker ( e.g. , immunoglobulin rearrangement , pattern DNA methylation , presence Epstein-Barr virus DNA ) . Patients undergo fludeoxyglucose F18 positron emission tomography periodically study . PROJECTED ACCRUAL : A total 35 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm classical Hodgkin 's lymphoma No lymphocytepredominant histology Stage II , III , IV disease Newly diagnose disease PATIENT CHARACTERISTICS : Performance status 02 Creatinine &lt; 2.0 mg/dL Bilirubin &lt; 5 mg/dL Not pregnant nursing No HIV positivity Hepatitis B surface antigen negative No active concurrent malignancy except superficial nonmelanoma skin cancer cervical carcinoma situ PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy Hodgkin 's lymphoma Steroids allow medically require chemotherapy initiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>adult lymphocyte depletion Hodgkin lymphoma</keyword>
	<keyword>adult mixed cellularity Hodgkin lymphoma</keyword>
	<keyword>adult nodular sclerosis Hodgkin lymphoma</keyword>
</DOC>